Life Science Investing Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Life Science Investing Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
